Dx & Vx Co., Ltd.
Financials
Valuation Metrics
Dx & Vx Co., Ltd.'s Market Cap is ₩2249B. At end of 2025 it was ₩3091B. Ranked #788 of 2,421 in KR market (top 33%), #356 of 1,640 on KOSDAQ (top 22%), #86 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 224.91B KRW | KR#788/2,421 Sec#86/231 |
| Revenue | 26.22B KRW | KR#2,077/2,421 Sec#145/231 |
| Net Income | -26.84B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 107.49B KRW | KR#1,723/2,421 Sec#135/231 |
| Net Assets | 83.89B KRW | KR#1,552/2,421 Sec#124/231 |
| Employees | 121 | KR#1,497/2,421 Sec#119/231 |
| Value | ||
| P/B | 2.68x | KR#2,072/2,421 Sec#162/231 |
| P/S | 8.58x | KR#2,253/2,421 Sec#160/231 |
| FCF Yield | -8.83% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -32.00% | KR#2,200/2,421 Sec#182/231 |
| ROA | -24.97% | KR#2,280/2,421 Sec#189/231 |
| Op. Margin | -80.17% | KR#2,288/2,421 Sec#168/231 |
| Revenue Growth | -9.44% | KR#1,914/2,421 Sec#177/231 |
| Financial Health | ||
| Debt Ratio | 28.14% | KR#543/2,421 Sec#60/231 |
| Total Debt | 10.72B KRW | KR#1,599/2,421 Sec#144/231 |
| FCF | -19.85B KRW | KR#1,891/2,421 Sec#178/231 |
| Cash | 28.30B KRW | KR#1,037/2,421 Sec#73/231 |
| Current Ratio | 4.14x | KR#363/2,421 Sec#56/231 |
| Performance | ||
| 1Y Return | 1.11% | KR#714/2,421 Sec#46/231 |
| 1M Return | -8.05% | KR#2,007/2,421 Sec#167/231 |
| From 52W High | -57.37% | KR#1,760/2,421 Sec#133/231 |
| 1Y MDD | -61.19% | KR#1,548/2,421 Sec#124/231 |
| Trading | ||
| Volume | 30,236 shares | KR#1,377/2,421 Sec#134/231 |
| Trading Value | 69.5M KRW | KR#1,710/2,421 Sec#175/231 |
| Foreign Own. | 4.91% | KR#871/2,421 Sec#77/231 |
| Per Share | ||
| EPS | -273 KRW | KR—/2,421 Sec—/231 |
| BPS | 852 KRW | KR#2,330/2,421 Sec#216/231 |
Company Info
DXVX, established in 2001, is a bio-healthcare specialized company that listed on KOSDAQ in 2015. It has expanded its business through the acquisition of Korea Biopharm in 2022, and the establishment of a Chinese subsidiary and acquisition of Evixgen in 2023. The medical diagnostics division focuses on NGS and DNA chip-based genomic diagnostics, along with the development and manufacturing of PCR molecular diagnostic and rapid immune diagnostic kits. The new drug development division aims to reduce financial risk by developing diverse pipelines and implementing stage-by-stage license transfers. DXVX is headquartered in Geumcheon-gu, Seoul.